您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Ozagrel HCl(OKY046 HCl KCT0809 Cataclot)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ozagrel HCl(OKY046 HCl KCT0809 Cataclot)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ozagrel HCl(OKY046 HCl KCT0809 Cataclot)图片
CAS NO:78712-43-3
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)264.71
FormulaC13H12N2O2.HCl
CAS No.78712-43-3
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 53 mg/mL (200.2 mM)
Water: 53 mg/mL (200.2 mM)
Ethanol: 6 mg/mL (22.7 mM)
Solubility (In vivo(E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylic acid hydrochloride
SynonymsOKY-046 HCl; KCT 0809; Cataclot; Xanbo; OKY046 HCl; Ozagrel hydrochloride, Ozagrel HCl; OKY 046 HCl; Ozagrel; KCT-0809; KCT0809; Ozagrel free acid
实验参考方法
In Vitro

In vitro activity: Ozagrel(OKY-046) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor. Ozagrel was selected as the best compound of highly selective inhibitors of TXA2 synthase. The inhibition of TXA2 synthase by ozagrel was more effective on human and rabbit enzymes than those of other species. Ozagrel increased 6-keto-PGF1 alpha, one of stable metabolites of PGI2, in various isolated cells and tissues perhaps via accumulated PG endoperoxides resulted by the inhibition of TXA2 synthase

In Vivo Ozagrel prevents oleic acid (OA) induced thromboxane A(2) generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increased monocyte chemoattractant protein-1 andinterleukin-8 mRNA expression in the whole lung of guinea pigs. Ozagrel (3 mg/kg) decreases both the area and volume of the cortical infarction after ischemia-reperfusion of the middle cerebral artery in rat. Ozagrel also has suppressive effects on the neurologic deficits in the microthrombosis rat model. Ozagrel improves the reduced spontaneously locomotor activity and the obstruction of motor coordination in the conscious cerebral ischemia-reperfusion mouse model. Ozagrel suppresses the decrease in specific gravity of the brain tissue induced by the occlusion-reperfusion in the conscious cerebral ischemia-reperfusion SHR model, and recovers the postischemic decrease in cortical PO(2) after middle cerebral artery occlusion-reperfusion in cats. Ozagrel also increases the level of 6-keto-PGF(1alpha), a metabolite of prostaglandin I(2) (PGI(2)), in the brain tissue after cerebral ischemia-reperfusion, and the administration of PGI(2) improves the reduced spontaneous locomotor activity in the conscious cerebral ischemia-reperfusion mouse model. Ozagrel administered intravenously 30 min before oleic acid injection prevents the decrease in Pao(2) and pulmonary vascular hyper-permeability in guinea-pigs. Ozagrel also prevents increases in lactate dehydrogenase activity, a measure of lung cell injury, TXB(2) and its weight ratio to 6-keto prostaglandin F(1alpha) in bronchoalveolar lavage fluid in guinea-pigs.
Animal modelRats
Formulation & Dosage3 mg/kg
References

J Pharmacol Sci. 2009 Oct;111(2):211-5; Pharmacology. 1999 Nov;59(5):257-65.